People
In November 2018, Chinese researcher He Jiankui announced he had used CRISPR gene editing to modify the CCR5 genes in the embryos of seven Chinese couples. This was met by widespread condemnation, investigations and a call for a global moratorium against that type of research.
Board appointment will help guide target identification and drug discovery
According to reports, Novartis veteran Jonathan Symonds is likely to be named the next chairman of the board.
At Kite, Shaw will focus on turning around the company’s flagship CAR-T treatment Yescarta, as well as focus on the development of other cancer-targeting cell therapies.
With a clear vision in mind Iperion Life Sciences Consultancy has taken the next step in realizing her mission.
Biotech and pharma companies strengthen their leadership teams with new appointments.
AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, announced the hiring of Jay Mohr as Chief Operating Officer, Chief Business Officer, and Head of Commercial Development.
Start Codon, a new model of life science and healthcare business accelerator, announced two appointments to its senior team.
Ergomed plc, a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce its intention to appoint Dr Jim Esinhart as a Non-Executive Director of the Company.
Recce Pharmaceuticals Ltd, the company developing a new class of synthetic antibiotics, announced that Dr John Prendergast has been appointed to Independent Chair with founder Dr Graham Melrose stepping back from the role of Executive Chair to Executive Director and Chief Research Officer.
PRESS RELEASES